시장보고서
상품코드
1426136

세계 ACE 억제제 시장 : 약제별, 투여 경로별, 적응증별, 최종 사용자별, 지역별, 기회, 예측(2017년-2031년)

ACE Inhibitors Market Assessment, Drugs, By Route of Administration, By Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F

발행일: | 리서치사: Market Xcel - Markets and Data | 페이지 정보: 영문 228 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

세계 ACE 억제제 시장 규모는 2023년 71억 6,000만 달러에 달했습니다. 이 시장은 2031년에는 108억 6,000만 달러에 달할 것으로 예측되고, 2024년부터 2031년의 예측 기간 동안 복합 연간 성장률(CAGR) 5.34%가 될 것으로 보입니다. 세계 ACE 억제제 시장은 고혈압과 같은 심혈관 장애의 유병률 상승으로 비용 효율적인 의약품에 대한 수요가 증가하고 있는 등 여러 요인에 의해 견인되고 있습니다. 고혈압 치료를 위한 혁신적인 신제품 투입은 시장 성장을 가속하는 주요 요인입니다. 또한 다양한 심혈관 질환 관리에서 ACE 억제제의 장점에 대한 인식이 높아지고, 약물 제제의 진보, ACE 억제제의 효능 및 안전성 프로파일 강화를 목적으로 한 연구 개발 활동 등의 요인도 시장 에 영향을 미칩니다.

ACE 억제제는 심장병 환자의 사망 예방과 건강 증진에 매우 유익합니다. 주요 시장 진출기업에 의한 신약의 개척과 ECG 등의 정기 검진에 관한 환자의 의식의 고조가 세계 ACE 억제제 시장의 성장을 가속하고 있습니다. 게다가 정부의 이니셔티브는 개발도상국과 저개발국에서 스크리닝 기술과 효율적인 의약품 개발에 대한 접근성을 개선하고 이러한 시장에서 ACE 억제제에 대한 접근성이 증가할 것으로 기대되고 있습니다.

세계 심혈관 질환 증가로 ACE 억제제 수요가 급증하고 있습니다. ACE 억제제는 정맥과 동맥을 이완시켜 혈압을 낮추는 중요한 역할을 담당합니다. 따라서 ACE 억제제는 생명을 위협하는 심장 질환을 예방하는 중요한 약제 역할을합니다. 미국 심장협회에 따르면 2020년에는 약 1,910만 명이 심혈관 질환으로 사망했다고 합니다. 허혈성 심장 질환은 전 세계적으로 약 2억 4,410만 명이 앓고 있습니다. ACE 억제제는 혈압과 관상 동맥 질환을 조절하고 심부전과 심장 마비를 예방하는 데 매우 효과적입니다. ACE 억제제의 장점과 잠재력에 대한 사람들의 의식이 증가함에 따라 ACE 억제제 수요는 세계적으로 일관되게 증가하고 있습니다.

본 보고서에서는 세계 ACE 억제제 시장에 대해 조사했으며,, 시장 개요와 함께 약제별, 투여경로별, 적응증별, 최종사용자별, 지역별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 조사 방법

제2장 프로젝트의 범위와 정의

제3장 주요 요약

제4장 세계 ACE 억제제 시장 전망(2017년-2031년)

  • 시장 규모와 예측
  • 약별별
  • 투여 경로별
  • 적응증별
  • 최종 사용자별
  • 지역별
  • 기업별 시장 점유율(%)(2023년)

제5장 세계 ACE 저해약 시장 전망, 지역별(2017년-2031년)

  • 북미
  • 유럽
  • 남미
  • 아시아태평양
  • 중동 및 아프리카

제6장 시장 매핑(2023년)

제7장 거시적 환경과 산업 구조

  • 수급 분석
  • 수출입 분석
  • 밸류체인 분석
  • PESTEL 분석
  • Porter's Five Forces 분석

제8장 시장 역학

제9장 규제 프레임워크과 혁신

제10장 주요 진입기업의 정세

제11장 가격 분석

제12장 사례 연구

제13장 주요 기업의 전망

  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca Plc.
  • Sanofi Winthrop Industries
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Lupin Pharmaceutical, Inc.
  • Sun Pharmaceutical Industries Limited
  • Bayer AG
  • Cipla Limited
  • AbbVie Inc.
  • Bristol-Myers Squibb Pharmaceuticals Limited

제14장 전략적 제안

제15장 문의와 면책사항

BJH 24.02.26

Global ACE inhibitors market size was valued at USD 7.16 billion in 2023 and is expected to reach USD 10.86 billion in 2031, with a CAGR of 5.34% for the forecast period between 2024 and 2031. The global ACE inhibitors market is driven by several factors, including the rising prevalence of cardiovascular disorders, such as hypertension, which has increased demand for cost-effective drugs. Introducing new innovative products for treating hypertension is a major factor driving the market growth. Additionally, the market is influenced by factors such as the growing awareness of the benefits of ACE inhibitors in managing various cardiovascular conditions, advancements in drug formulations, and research and development activities aimed at enhancing ACE inhibitors' efficacy and safety profiles.

ACE Inhibitors are highly beneficial in preventing death and promoting health in heart patients. The development of novel drugs by the key market players and rising awareness among patients regarding regular check-ups, such as ECG, are driving the growth of the global ACE inhibitors market. Moreover, governmental initiatives are expected to improve access to screening technologies and efficient drug developments in developing and under-developed countries, which will increase access to ACE inhibitors in these markets.

Increasing Prevalence of Cardiovascular Patients

There has been a surge in demand for ACE Inhibitors due to rising number of cardiovascular diseases worldwide. ACE Inhibitors plays a crucial role in relaxing the veins and arteries to lower the blood pressure. Due to it, the inhibitors act as an important drug in preventing life-threating heart condition. According to American Heart Association, around 19.1 million people died in 2020 due to cardiovascular diseases. Around 244.1 million people were affected by ischemic heart diseases globally. ACE inhibitors are highly efficient in controlling blood pressure and coronary artery diseases and prevents heart failures and heart attack. There is an increased awareness among the people regarding benefits and potential of ACE inhibitors, due to which, there has been a consistent increase in demand for ACE inhibitors globally.

ACE Inhibitors are Receiving Significant Investments from Stakeholders

With high prevalence of cardiovascular diseases, there is a high demand to invest in research and development in the medicines for management of heart diseases. ACE Inhibitors have the potential to control and prevent heart health outcomes such as strokes, ischaemic heart diseases. Due to it, pharmaceuticals companies are continuously investing and launching modern ACE inhibitors.

In February 2023, Travere Therapeutics, Inc. announced FDA approval for Filspari to reduce proteinuria in adults, who are affected by IgAN, which is a rare kidney disease. Filspari is an ACE inhibitor which has proved to be beneficial for the patients suffering from IgAN and have the potential to reduce proteinuria and further prevent kidney failure.

Government Initiatives

As the prevalence of chronic diseases is increasing globally, governments are consistently launching initiatives and policies to improve access to ACE inhibitors in developed and emerging countries. Government support for research and development in the pharmaceutical industry, including the development of ACE inhibitors, is a key factor in driving innovation and market growth. Additionally, regulatory approval process and healthcare policies can impact market dynamics and the availability of ACE inhibitors.

For instance, World Heart Vision 2030 was launched by the World Heart Federation to bring policies and programs to improve cardiovascular health and reduce cardiovascular conditions such as heart failure and heart attack. Several steps were taken under these initiatives, such as increasing awareness regarding therapeutical approaches towards heart health, research and development for efficient drug discoveries, and improved accessibility to heart care facilities.

Rapid Growth in Demand for Lisinopril Drugs

Among the drugs segment, Lisinopril holds a significant share in global ACE inhibitors market. Tremendous research and development activities and increased investments by key market players in the segment are leading to the huge demand for Lisinopril Drugs in the ACE inhibitors market. Moreover, its potential to control blood pressure by widening blood vessels is the main reason behind its increasing demand. Due to this, many key market players are including drugs in their product portfolio. In September 2023, Almatica Pharma LLC., a global leader in developing medicines for several therapy areas such as cardiovascular diseases, psychiatry, and pain management recently received FDA approval for Zestril (lisinopril), specially manufactured for managing hypertension. Supportive regulatory systems are enabling pharmaceutical companies to invest and launch drugs for these heart conditions.

North America Holds the Largest Share in the Market

North America holds the highest share of the global ACE inhibitors market. Robust healthcare infrastructure and advanced healthcare facilities are some of the factors that make North America a global leader in the healthcare market. Growing awareness about the importance and benefits of screening and early diagnosis in preventing heart related diseases is driving the demand for ACE inhibitors globally. Growing focus on preventive healthcare, along with increasing availability of healthcare professionals, further leads to growing usage of ACE inhibitors for reducing the probability of mortality due to cardiovascular disorders. With the growing prevalence of cardiovascular diseases in the USA, there is a huge demand for ACE Inhibitors in the region. For instance, according to CDC, the most common cause of death in the United States is heart disease, and over 805,000 Americans get a heart attack each year. Due to this, the demand for ACE inhibitors is expected to grow in North America.

Future Market Scenario

Global ACE inhibitors market is expected to grow in the coming years, due to multiple factors. Primarily, the increasing elderly population, which is prone to cardiovascular and other chronic diseases. It has further led to increase in demand for ACE Inhibitors to provide treatment. Rising awareness regarding the screening programs, along with increased research and developments are also contributing to the market's growth. Additionally, the market is being influenced by the growing demand for cost-effective drugs and the development of combination therapies such as ACE Inhibitors and diuretics and ACE Inhibitors and angiotensin receptor blockers. Geographically, Asia-Pacific is expected to experience the fastest growth, driven by a sizable population base, rising urbanization, and an increase in the prevalence of cardiovascular diseases.

Key Players Landscape and Outlook

In the ACE inhibitors market, public and private companies are progressively establishing initiatives, strategic partnerships, and distribution agreements, which are pivotal in propelling the global ACE inhibitors market's expansion. These alliances empower firms to adapt to each other's strengths, gain access to new markets and technologies, and pool resources for research and development endeavors. Distribution agreements enable companies to broaden their market presence at an international level.

In January 2023, AstraZeneca acquired CinCor Pharma, Inc., a biopharmaceutical company, working on novel treatments for hypertension as well as chronic kidney disease by developing medicines such as ACE inhibitors. The strategic acquisition will enable the company to enhance its portfolio for the management of cardiovascular diseases, which will further expand the company's global presence.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global ACE Inhibitors Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Drugs
    • 4.2.1. Lisinopril
    • 4.2.2. Ramipril
    • 4.2.3. Enalapril
    • 4.2.4. Benazepril
    • 4.2.5. Fosinopril
    • 4.2.6. Captopril
    • 4.2.7. Moexipril
    • 4.2.8. Others
  • 4.3. By Route of Administration
    • 4.3.1. Oral
    • 4.3.2. Injectable
  • 4.4. By Indication
    • 4.4.1. Heart Failure
    • 4.4.2. Hypertension
    • 4.4.3. Diabetes
    • 4.4.4. Heart Attack
    • 4.4.5. Chronic Kidney Disease
    • 4.4.6. Others
  • 4.5. By End-user
    • 4.5.1. Retail Pharmacy
    • 4.5.2. Hospital Pharmacy
    • 4.5.3. Online Pharmacy
    • 4.5.4. E-commerce Websites
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. South America
    • 4.6.4. Asia-Pacific
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global ACE Inhibitors Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Drugs
      • 5.1.2.1. Lisinopril
      • 5.1.2.2. Ramipril
      • 5.1.2.3. Enalapril
      • 5.1.2.4. Benazepril
      • 5.1.2.5. Fosinopril
      • 5.1.2.6. Captopril
      • 5.1.2.7. Moexipril
      • 5.1.2.8. Others
    • 5.1.3. By Route of Administration
      • 5.1.3.1. Oral
      • 5.1.3.2. Injectable
    • 5.1.4. By Indication
      • 5.1.4.1. Heart Failure
      • 5.1.4.2. Hypertension
      • 5.1.4.3. Diabetes
      • 5.1.4.4. Heart Attack
      • 5.1.4.5. Chronic Kidney Disease
      • 5.1.4.6. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Retail Pharmacy
      • 5.1.5.2. Hospital Pharmacy
      • 5.1.5.3. Online Pharmacy
      • 5.1.5.4. E-commerce Websites
    • 5.1.6. United States*
      • 5.1.6.1. By Drugs
      • 5.1.6.1.1. Lisinopril
      • 5.1.6.1.2. Ramipril
      • 5.1.6.1.3. Enalapril
      • 5.1.6.1.4. Benazepril
      • 5.1.6.1.5. Fosinopril
      • 5.1.6.1.6. Captopril
      • 5.1.6.1.7. Moexipril
      • 5.1.6.1.8. Others
      • 5.1.6.2. By Route of Administration
      • 5.1.6.2.1. Oral
      • 5.1.6.2.2. Injectable
      • 5.1.6.3. By Indication
      • 5.1.6.3.1. Heart Failure
      • 5.1.6.3.2. Hypertension
      • 5.1.6.3.3. Diabetes
      • 5.1.6.3.4. Heart Attack
      • 5.1.6.3.5. Chronic Kidney Disease
      • 5.1.6.3.6. Others
      • 5.1.6.4. By End-user
      • 5.1.6.4.1. Retail Pharmacy
      • 5.1.6.4.2. Hospital Pharmacy
      • 5.1.6.4.3. Online Pharmacy
      • 5.1.6.4.4. E-commerce Websites
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Drugs
  • 6.2. By Route of Administration
  • 6.3. By Indication
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Novartis AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Pfizer Inc.
  • 13.3. AstraZeneca Plc.
  • 13.4. Sanofi Winthrop Industries
  • 13.5. Boehringer Ingelheim International GmbH
  • 13.6. Merck & Co., Inc.
  • 13.7. Lupin Pharmaceutical, Inc.
  • 13.8. Sun Pharmaceutical Industries Limited
  • 13.9. Bayer AG
  • 13.10. Cipla Limited
  • 13.11. AbbVie Inc.
  • 13.12. Bristol-Myers Squibb Pharmaceuticals Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제